IL17A and rheumatoid arthritis: The medication also reduced pathology of RA through neutrophil recruitment inhibition and various pro-inflammatory cytokines (monocyte chemotactic protein (MCP)-1, IFN-γ, TNF-α, IL-17, IL-6) (144).